Tvardi Therapeutics, Inc. Stock Option Agreement Granted Under 2018 Stock Incentive PlanStock Option Agreement • December 18th, 2024 • Cara Therapeutics, Inc. • Pharmaceutical preparations
This Stock Option Agreement (this “Agreement”) is made between Tvardi Therapeutics, Inc., a Delaware corporation (the “Company”), and the Participant pursuant to the 2018 Stock Incentive Plan (the “Plan”).
Breakthrough Medicines for Cancer, Chronic Inflammation & FibrosisEmployment Agreement • December 18th, 2024 • Cara Therapeutics, Inc. • Pharmaceutical preparations
On behalf of Tvardi Therapeutics, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company, should you accept our offer.
November 19, 2018Employment Agreement • December 18th, 2024 • Cara Therapeutics, Inc. • Pharmaceutical preparations • Delaware
On behalf of Tvardi Therapeutics, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company, should you accept our offer.
December 5, 2022Employment Agreement • December 18th, 2024 • Cara Therapeutics, Inc. • Pharmaceutical preparations
On behalf of Tvardi Therapeutics, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company, should you accept our offer.
EXCLUSIVE LICENSE AGREEMENT Re: BCM BLG # [***] Entitled “Chemical Probes That Competitively and Selectively Inhibit Stat3 Activation”, developed by [***]Exclusive License Agreement • December 18th, 2024 • Cara Therapeutics, Inc. • Pharmaceutical preparations • Texas
This Exclusive License Agreement (hereinafter called “Agreement”), to be effective as of the 16th day of July, 2012 (hereinafter called “Agreement Date”), is by and between Baylor College of Medicine (hereinafter called “BCM”), a Texas nonprofit organization having its principal place of business at One Baylor Plaza, Houston, Texas 77030, and Stem Med, Limited Partnership, a corporation organized under the laws of Texas and having a principal place of business at 7000 Fannin St., Houston, Texas 77030, and its Affiliates (hereinafter, collectively referred to as “LICENSEE”).
Tvardi Therapeutics, Inc.Restricted Stock Agreement • December 18th, 2024 • Cara Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Restricted Stock Agreement (the “Agreement”) is made this [ ] day of [ ], 20[ ], between Tvardi Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Participant”).
EXCLUSIVE LICENSE AGREEMENT Re: BCM BLG # [***]; NIH# [***] Entitled “Stat3 inhibition to treat disorders involving mast cell degranulation”Exclusive License Agreement • December 18th, 2024 • Cara Therapeutics, Inc. • Pharmaceutical preparations • Texas
This Exclusive License Agreement (hereinafter called “Agreement”), to be effective as of the 19th day of June, 2015 (hereinafter called “Agreement Date”), is by and between Baylor College of Medicine (hereinafter called “BCM”), a Texas nonprofit organization having its principal place of business at One Baylor Plaza, Houston, Texas 77030, and StemMed Ltd., a corporation organized under the laws of Texas and having a principal place of business at 7000 Fannin St., Houston, Texas 77030, and its Affiliates (hereinafter, collectively referred to as “LICENSEE”).
